<DOC>
	<DOCNO>NCT00819468</DOCNO>
	<brief_summary>This study compare pharmacokinetic profile teduglutide healthy subject normal hepatic function subject moderate hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics 20 mg Teduglutide Subjects With Moderately Impaired Hepatic Function Compared Healthy Subjects With Normal Hepatic Function</brief_title>
	<detailed_description>24 subject ( equally divide subject normal hepatic function moderate hepatic impairment ( define protocol Child-Pugh classification grade B score 7-9 ) give single injection teduglutide ( 20mg ) subcutaneous injection abdomen . Blood sample would take within 30 minute dose 24 hour post-dose . Subjects group match sex , age , BMI , renal function .</detailed_description>
	<criteria>Adult male female 18 85 year age BMI 18 40 , inclusive Creatinine clearance &gt; 50 mL/min Able understand willing sign inform consent form ( ICF ) Willing able confine study site approximately 2.5 day Female subject postmenopausal , surgically sterilize , woman childbearing potential ( WOCBP ) use effective form birth control study WOCBP must negative urine Î²hCG result screening ( Days 28 2 ) checkin ( Day 1 ) Negative urine test select drug abuse alcohol screen checkin ( Inclusion Subjects Impaired Hepatic Function ( addition criterion ) : Documented moderately impaired hepatic function define total score 7 9 ChildPugh Classification screen checkin No clinically significant change disease status within 3 month prior study entry Abnormal laboratory result related subject 's underlying condition clinically stable deem investigator Abstained alcohol use within 90 day prior study entry hepatic impairment know secondary alcohol abuse On medication and/or treatment regimen , opinion investigator , underlie disease control Subjects normal hepatic function match collectively group gender , age , BMI subject moderately impaired hepatic function . Subjects normal hepatic function also match individually subject moderately impaired hepatic function regard renal function In addition inclusion criterion # 1 8 , subject normal hepatic function must also meet follow inclusion criterion eligible participation study : Similar level renal function base CockroftGault equation match subject moderately impaired hepatic function Medically healthy normal clinically insignificant clinical result screen checkin Donated 1 pint blood blood product within 7 day prior study , and/or blood plasma donation within 7 day prior study Participated investigational drug trial within 30 day prior study entry Have hemoglobin level &lt; 10.0 g/dL screening ( Days 28 2 ) Have condition , opinion investigator sponsor , would make unsuitable study Subjects Impaired Hepatic Function ( addition exclusion criterion 14 ) : Acceptable ChildPugh score ( Grade B , score 7 9 ) , associate condition metastatic cancer rather impair hepatic function Subjects Normal Hepatic Function ( addition exclusion criterion 14 History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease History evidence congenital nonhemolytic hyperbilirubinemia History evidence gallstone disease stomach intestinal surgery , exception appendectomy History evidence colorectal cancer History evidence malabsorption , pancreatic disease gastrointestinal disorder , irritable bowel syndrome , Crohn 's disease ulcerative colitis Taking prescription overthecounter medication ( exception daily low dose aspirin regimen and/or birth control ) 7 day precede confinement clinical research unit , and/or anticipate need use prescription overthecounter medication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>